Our aims were to determine the clinical impact of oral valganciclovir (VGCV) in infants aged ≤2 months with congenital cytomegalovirus (CMV) disease and evaluate the efficacy of VGCV when initiated beyond the neonatal period. The multicenter, single-arm, open-label clinical trial was conducted in Japan. Twenty-five infants aged ≤2 months with congenital CMV disease involving the central nervous system were enrolled and treated with VGCV for 6 months. The primary endpoint was the change in the whole blood CMV load before and after treatment. The secondary endpoint was the change in the auditory brainstem response (ABR) before and after treatment. Changes in ABR were assessed between the younger and older age groups (≤ and >30 days at treatment initiation). Of the 25 patients, one was excluded owing to epilepsy before VGCV administration. The median change in the CMV DNA level in whole blood was −246.0 IU/mL. The best ear and total ear assessments based on ABR were categorized as (improved + unchanged) after treatment for 100% and 93.8%, respectively. No differences in hearing efficacy were observed between the younger and older age groups. Oral VGCV is a potential therapeutic option for treating infants aged ≤2 months with congenital CMV disease.
This article reports the case of a female with late infantile neuronal ceroid lipofuscinosis who developed right and left anterior bundle branch blocks and episodic bradycardia at 23 years of age. Several episodes of supraventricular tachycardia manifested at 23 and 27 years of age. In addition, a transient second‐degree atrioventricular conduction block also emerged at 27 years of age. Atrial fibrillation and aggravation of the atrioventricular conduction block resulted in progressive bradycardia and cardiac death at the age of 28 years. Cardiac involvement and accumulation of lipopigments in the myocardium and cardiac conduction system have been recognized in juvenile neuronal ceroid lipofuscinosis, but this is the first report to describe progressive conduction defects in a case of late infantile neuronal ceroid lipofuscinosis.
Objective: To investigate the association between hypoxic‐ischaemic insult timing and brain injury type in infants with severe cerebral palsy (CP).Design: Longitudinal study.Setting: Database of the Recurrence Prevention Committee, Japan Obstetric Compensation System for Cerebral Palsy.Sample: Infants with severe CP born at ≥34 weeks of gestation.Methods: The intrapartum fetal heart rate (FHR) strips were categorised as continuous bradycardia; persistently non‐reassuring (NR‐NR); reassuring‐prolonged deceleration (R‐PD); Hon's pattern (R‐Hon); persistently reassuring (R‐R); and unclassified. The brain magnetic resonance imaging (MRI) scans were categorised based on the predominant site involved: basal ganglia‐thalamus (BGT); white matter (WM); watershed (WS); stroke; normal; and unclassified.Main outcome measures: Manifestations of the brain MRI types and the association between FHR evolution pattern and MRI type were analysed.Results: Among 672 eligible infants, 76% had BGT‐dominant injury, 5.4% WM, 1.2% WS, 1.6% stroke, 1.9% normal, and 14% unclassified. Placental abruption and small‐for‐gestational age were associated with an increased (adjusted odds ratio [aOR] 8.02) and decreased (aOR 0.38) risk of BGT injury, respectively. The majority of infants had BGT injury in most FHR groups (bradycardia, 97%; NR‐NR, 75%; R‐PD, 90%; R‐Hon, 76%; and R‐R, 45%). The risk profiles in case of BGT in the NR‐NR group were similar to those in the R‐PD and R‐Hon groups.Conclusion: BGT‐dominant brain damage accounted for three‐fourths of the cases of CP in term or near‐term infants, even in prenatal onset cases. Hypoxic‐ischaemic insult has a major impact on CP development during the antenatal period.Tweetable Basal ganglia‐thalamus injury constitutes 76% of severe cerebral palsy cases, predominant even in antenatal‐onset cases.